| Literature DB >> 34879422 |
Monika Zdanyte1, Dominik Rath1, Meinrad Gawaz1, Tobias Geisler1.
Abstract
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection is associated with high risk of venous and arterial thrombosis. Thrombotic complications, especially pulmonary embolism, lead to increased all-cause mortality in both intensive care unit and noncritically ill patients. Damage and activation of vascular endothelium, platelet activation, followed by thrombotic and fibrinolytic imbalance as well as hypercoagulability are the key pathomechanisms in immunothrombosis leading to a significant increase in thromboembolism in coronavirus disease 2019 (COVID-19) compared with other acute illnesses. In this review article, we discuss the incidence and prognosis, diagnosis, prevention, and treatment of venous thromboembolism in patients with COVID-19 disease, based on clinical experience and research available to date. Thieme. All rights reserved.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34879422 DOI: 10.1055/a-1661-0283
Source DB: PubMed Journal: Hamostaseologie ISSN: 0720-9355 Impact factor: 2.145